Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-11-13 22:30 |
Informations privilégiées / Autres communiqués
|
French | 195.1 KB | ||
| 2019-11-08 22:30 |
Total number of voting rights and capital / Information on the total number of …
|
English | 64.6 KB | ||
| 2019-11-08 22:30 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 65.2 KB | ||
| 2019-11-06 22:47 |
Quarterly financial reporting / Third quarter financial report
|
English | 466.3 KB | ||
| 2019-11-06 22:47 |
Information financière trimestrielle / Information financière du troisième trim…
|
French | 388.7 KB | ||
| 2019-10-31 21:30 |
Informations privilégiées / Autres communiqués
|
French | 129.9 KB | ||
| 2019-10-31 21:30 |
Inside Information / Other news releases
|
English | 194.4 KB | ||
| 2019-10-29 21:30 |
Informations privilégiées / Autres communiqués
|
French | 164.9 KB | ||
| 2019-10-29 21:30 |
Inside Information / Other news releases
|
English | 157.7 KB | ||
| 2019-09-06 23:16 |
Total number of voting rights and capital / Information on the total number of …
|
English | 64.6 KB | ||
| 2019-09-06 23:16 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 65.3 KB | ||
| 2019-08-07 22:30 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 65.3 KB | ||
| 2019-08-07 22:30 |
Total number of voting rights and capital / Information on the total number of …
|
English | 64.3 KB | ||
| 2019-08-06 22:30 |
Half yearly financial reports and audit reports/limited reviews / Half yearly f…
|
English | 498.0 KB | ||
| 2019-08-06 22:30 |
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier …
|
French | 516.7 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
